Skip to main content
. 2012 Jun 22;61(12):2357–2366. doi: 10.1007/s00262-012-1297-2

Fig. 2.

Fig. 2

Modulation of dysregulated Treg and NK cells in malignant patients. After type 1 treatment, the overinduced Treg (a, CD4+CD25+high) in a representative malignant patient could be modulated to 0.4 % (b), and the NK cells remained normal (c, d). After type 2 treatment, the downregulated NK (e, CD3CD56+) in a representative malignant patient could be elevated to 21.9 % (f), and the Treg remained normal (g, h)